Search

Your search keyword '"Rayzman, Veronika"' showing total 11 results
Start Over Author "Rayzman, Veronika"
11 results on '"Rayzman, Veronika"'

3. Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation

Author

Cao, Helen, primary, Biondo, Mark, additional, Lioe, Hadi, additional, Busfield, Samantha, additional, Rayzman, Veronika, additional, Nieswandt, Bernhard, additional, Bork, Konrad, additional, Harrison, Leonard C., additional, Auyeung, Priscilla, additional, Farkas, Henriette, additional, Csuka, Dorottya, additional, Pelzing, Matthias, additional, Dower, Steve, additional, Wilson, Michael J., additional, Nash, Andrew, additional, Nolte, Marc W., additional, and Panousis, Con, additional

Published
2018
Full Text
View/download PDF

4. Therapeutic Targeting of the G-CSF Receptor Reduces Neutrophil Trafficking and Joint Inflammation in Antibody-Mediated Inflammatory Arthritis

Author

Campbell, Ian K., primary, Leong, David, additional, Edwards, Kirsten M., additional, Rayzman, Veronika, additional, Ng, Milica, additional, Goldberg, Gabrielle L., additional, Wilson, Nicholas J., additional, Scalzo-Inguanti, Karen, additional, Mackenzie-Kludas, Charley, additional, Lawlor, Kate E., additional, Wicks, Ian P., additional, Brown, Lorena E., additional, Baz Morelli, Adriana, additional, Panousis, Con, additional, Wilson, Michael J., additional, Nash, Andrew D., additional, McKenzie, Brent S., additional, and Andrews, Arna E., additional

Published
2016
Full Text
View/download PDF

5. CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors

Author

Panousis, Con, primary, Dhagat, Urmi, additional, Edwards, Kirsten M., additional, Rayzman, Veronika, additional, Hardy, Matthew P., additional, Braley, Hal, additional, Gauvreau, Gail M., additional, Hercus, Timothy R., additional, Smith, Steven, additional, Sehmi, Roma, additional, McMillan, Laura, additional, Dottore, Mara, additional, McClure, Barbara J., additional, Fabri, Louis J., additional, Vairo, Gino, additional, Lopez, Angel F, additional, Parker, Michael W., additional, Nash, Andrew D., additional, Wilson, Nicholas J., additional, Wilson, Michael J., additional, and Owczarek, Catherine M., additional

Published
2015
Full Text
View/download PDF

7. A Factor XIIa Inhibitory Antibody Provides Thromboprotection in Extracorporeal Circulation Without Increasing Bleeding Risk

Author

Larsson, Magnus, primary, Rayzman, Veronika, additional, Nolte, Marc W., additional, Nickel, Katrin F., additional, Björkqvist, Jenny, additional, Jämsä, Anne, additional, Hardy, Matthew P., additional, Fries, Marion, additional, Schmidbauer, Stefan, additional, Hedenqvist, Patricia, additional, Broomé, Michael, additional, Pragst, Ingo, additional, Dickneite, Gerhard, additional, Wilson, Michael J., additional, Nash, Andrew D., additional, Panousis, Con, additional, and Renné, Thomas, additional

Published
2014
Full Text
View/download PDF

8. CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors.

Author

Panousis, Con, Dhagat, Urmi, Edwards, Kirsten M., Rayzman, Veronika, Hardy, Matthew P., Braley, Hal, Gauvreau, Gail M., Hercus, Timothy R., Smith, Steven, Sehmi, Roma, McMillan, Laura, Dottore, Mara, McClure, Barbara J., Fabri, Louis J., Vairo, Gino, Lopez, Angel F, Parker, Michael W., Nash, Andrew D., Wilson, Nicholas J., and Wilson, Michael J.

Published
2016
Full Text
View/download PDF

10. CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors

Author

Mara Dottore, Veronika Rayzman, Michael J. Wilson, Catherine M. Owczarek, Matthew P. Hardy, Timothy R. Hercus, Gino Vairo, Gail M. Gauvreau, Nicholas J. Wilson, Barbara J. McClure, Angel F. Lopez, Laura McMillan, Kirsten Edwards, Roma Sehmi, Steven G. Smith, Urmi Dhagat, Louis Fabri, Michael W. Parker, Hal Braley, Con Panousis, Andrew D. Nash, Panousis, Con, Dhagat, Urmi, Edwards, Kirsten M, Rayzman, Veronika, Hercus, Timothy R, Dottore, Mara, McClure, Barbara J, Lopez, Angel F, and Owczarek, Catherine M

Subjects
0301 basic medicine, Receptor complex, medicine.drug_class, medicine.medical_treatment, Immunology, Antigen-Antibody Complex, Biology, Monoclonal antibody, Crystallography, X-Ray, Epitope, Cytokine Receptor Common beta Subunit, 03 medical and health sciences, Antibodies, Monoclonal, Murine-Derived, Epitopes, Mice, β common receptor, medicine, cytokine, Immunology and Allergy, Animals, Humans, eosinophil, Receptor, Interleukin 5, Interleukin 3, affinity maturation, IL-5, IL-3, Granulocyte-Macrophage Colony-Stimulating Factor, GM-CSF, asthma, Eosinophils, 030104 developmental biology, Cytokine, therapeutic antibody, Interleukin-3, myeloid, phage display, Interleukin-5, Affinity maturation, Reports
Abstract

The β common-signaling cytokines interleukin (IL)-3, granulocyte-macrophage colony stimulating factor (GM-CSF) and IL-5 stimulate pro-inflammatory activities of haematopoietic cells via a receptor complex incorporating cytokine-specific α and shared β common (βc, CD131) receptor. Evidence from animal models and recent clinical trials demonstrate that these cytokines are critical mediators of the pathogenesis of inflammatory airway disease such as asthma. However, no therapeutic agents, other than steroids, that specifically and effectively target inflammation mediated by all 3 of these cytokines exist. We employed phage display technology to identify and optimize a novel, human monoclonal antibody (CSL311) that binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. The binding epitope of CSL311 on the βc receptor was defined by X-ray crystallography and site-directed mutagenesis. CSL311 has picomolar binding affinity for the human βc receptor, and at therapeutic concentrations is a highly potent antagonist of the combined activities of IL-3, GM-CSF and IL-5 on primary eosinophil survival in vitro. Importantly, CSL311 inhibited the survival of inflammatory cells present in induced sputum from human allergic asthmatic subjects undergoing allergen bronchoprovocation. Due to its high potency and ability to simultaneously suppress the activity of all 3 β common cytokines, CSL311 may provide a new strategy for the treatment of chronic inflammatory diseases where the human βc receptor is central to pathogenesis. The coordinates for the βc/CSL311 Fab complex structure have been deposited with the RCSB Protein Data Bank (PDB 5DWU). Refereed/Peer-reviewed

Published
2015

11. High-Throughput IgG Reformatting and Expression Using Hybrid Secretion Signals and InTag Positive Selection Technology.

Author

Sansome G, Rayzman V, Kiess I, Wilson MJ, Panousis C, and Chen CG

Subjects
Humans, Bodily Secretions, Cell Surface Display Techniques, Immunoglobulin Fab Fragments genetics, Technology, Immunoglobulin G genetics, Bacteriophages
Abstract

We have previously published protocols for high-throughput IgG reformatting and expression, that enable rapid reformatting of phage-displayed antibody Fab fragments into a single dual expression vector for full IgG expression in Expi293F cells (Chen et al. Nucleic Acids Res 42:e26, 2014; Chen et al. Methods in Molecular Biology, vol 1701, 2018). However, when working with phage clones from a naïve library containing highly diverse N-terminal sequences, where the 5' PCR primers bind, the PCR step can become cumbersome. To overcome this limitation, we have investigated and found that the C-terminal 7 amino acid residues of the human antibody VH1 secretion signal can be replaced with those from ompA or pelB bacterial signals to form hybrid signal sequences that can drive strong IgG expression in Expi293F cells. The use of such hybrid signals allows any Fab fragment in the library to be amplified and cloned into the IgG expression vector using only a single 5' PCR primer targeting the bacterial secretion signal of the light or heavy chain, thus dramatically simplifying the IgG reformatting workflow., (© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results